Welcome to BioSeeker Group!

Breast Cancer - Therapeutic And Competitive Insights

Additional Information

Published Date Feb 28, 2007
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 107
PDF Fact Sheet View Fact Sheet for the report Breast Cancer - Therapeutic And Competitive Insights in PDF
Format PDF
Publisher BioSeeker Group
Product Line View All Available Cancer Highlights Reports

Availability: In stock

$1,950.00

Quick Overview

Gain insight into the current challenges and commercial opportunities associated with breast cancer therapy.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Breast Cancer - Therapeutic And Competitive Insights.

    To find out more about Breast Cancer - Therapeutic And Competitive Insights, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Breast Cancer - Therapeutic And Competitive Insights is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Introduction

Overall approximately 3 million women in the US are living with breast cancer. But, even with an increasing incidence, the mortality rate has dropped slightly during the last 10-15 years. The most dramatic decrease is seen in younger patients (<50 years). In the past decade the regulatory authorities in US have approved five hormone-based therapies (Faslodex, Femara, Aromasin, Nolvadex and Arimidex), two chemotherapies (Xeloda and Taxotere) and one monoclonal antibody (Herceptin) as a treatment option for breast cancer. AstraZeneca reported increased sales of Arimidex during 2005 up 38% to $1.2 billion. Faslodex increased (+39%) to $140 million whereas Nolvadex decreased (-16%) to $114 million. Novartis reported that Femara increased it sell value by +30% to $326 million for the first 6 months in 2006. Net U.S. sales of Herceptin increased 56% to $747.2 million in 2005 and 18% to $479.0 million during 2004. According to UK estimates, the switching of 100 000 women from tamoxifen to Arimidex will cost nearly 100 million.

Research and analysis highlights

In the report "Breast Cancer - A Therapeutic & Competitive Insight" BioSeeker does not only describe and analyze the latest years of progress but as well provide an insight and framework to understand the complex field of breast cancer therapeutics. In this report, we provide one of the most comprehensive coverage of the R&D trends to set the future marketplace. BioSeeker presents both an overview and a detailed description on the progress of key drugs in Phase III and II development, together with general descriptions on drugs and targets. We have identified 170 drug candidates in clinical stage of development and more than 100 companies are involved in the development of these drugs. Among these drugs we clearly see substantial progress while others have failed. There will be a more intense competition in this market and current treatments will be changed for the benefit of more innovative therapies. Hormone modifying therapies together with different chemotherapeutic schedules have been of highest intrest during the last years of progress. A vast amount of new clinical research data has emerged and several new clinical trials have been iniated and others generated new results. Protein kinase inhibitors and epothilones have generated substantial amount of new research data in this field. But, other strategies seem not successful and we are still waiting new information regarding their progress.

Scope of this report

  • Thorough examination of status and impact of several novel drugs in development
  • Discussion of the challenges in current and future treatment strategies
  • Anticancer pipeline of most companies in the field

Key reasons to read this report

  • Explore the strengths and weaknesses associated with compounds in clinical development. Scientific rationale for most novel therapeutics in breast cancer R&D, and the results of clinical trials to date
  • Gain insight into the current challenges and commercial opportunities associated with breast cancer therapy
  • One hundred high quality references

Some of the drugs included in this analysis:
4HPR, Anastrozole, Arzoxifene, Bevacizumab, Bortezomib, BMS-247550, Erlotinib, Exemestane, Fulvestrant, Gefitinib, Goserelin, Imatinib, KOS-862, Lapatinib, Letrozole, Lonafarnib, NX473, Patupilone, Pemetrexed, Temsirolimus, Theratope, Tipifarnib, Trastuzumab, SDX-105.

Some of the companies included in this analysis:
AstraZeneca, Baxter International, Biomira, Bristol Myers-Squibb, Eli Lilly, Genentech,
GlaxoSmithKline, GTx, Isis Pharmaceuticals, Johnson and Johnson, Lorus Therapeutics, Merck, Millennium Pharmaceutical, NeoRx, Novartis Pharmaceuticals, Pfizer, Roche, Salmedix, Schering-Plough, Wyeth, YM BioSciences
 

1 Executive Summary

2 Cancer Highlights

3 Methodology

4 4.1 Boxes
4.2 Tables

5 Introduction
5.1 Disease Definitions
5.2 Etiology
5.3 Epidemiology
5.4 Prognosis

6 Current Treatment Strategies
6.1 Localized Disease
6.2 Advanced Disease

7 Progress in Current Treatment Strategies
7.1 Hormone Based Therapies
7.2 Antibodies
7.3 Chemotherapy

8 Key Therapeutic Strategies for Future Therapies
8.1 Therapeutic Type, Targets & Mechanisms

9 Competitive Landscape in Drug Development: The Late Stage Pipeline
9.1 The Epothilones
9.2 Cell Cycle & Apoptosis
9.3 Protein Kinase Inhibitors
9.4 Immunotherapy

10 Current Drug Development: The Early Stage Pipeline
10.1 DNA Targeting
10.2 FTIs
10.3 Antisense
10.4 New Hormone Modulators.
10.5 Other

11 Drug Index

12 Company Index 18H

35H13 Disclaimer 19H
36H13.1 Liability 120H107
37H13.2 Completeness 121H

4.1 List of Boxes
38HBox 1: Ongoing Phase III Studies Anastrozole 12
39HBox 2: Ongoing Phase III Studies Letrozole 123H
40HBox 3: Ongoing Phase III Studies Exemestane 124H
41HBox 4: Ongoing Phase III Studies Goserelin 125H
42HBox 5: Ongoing Phase III Studies Fulvestrant 126H
43HBox 6: Ongoing Phase III Studies Trastuzumab 127H
4HBox 7: Quick Facts - BMS-247550 128H
45HBox 8: Quick Facts - Temsirolimus 129H
Box 9: Quick Facts - SDX-105
Box 10: Quick Facts - 4HPR
Box 11: Quick Facts - Lapatinib
Box 12: Quick Facts - Bevacizumab
Box 13: Quick Facts - Theratope
Box 14: Erlotinib
Box 15: Gefitinib
Box 16: Imatinib
Box 17: Pemetrexed
Box 18: NX473
Box 19: Lonafarnib
Box 20: Tipifarnib
Box 21: Bortezomib
Box 22: Arzoxifene
Box 23: Patupilone
Box 24: KOS-862

4.2 List of Tables
Table 1: The Stage System
Table 2: Risk Factors.
Table 3: List of Approved Drugs and Their Mechanisms of Action.
Table 4: Hormonal Treatment Strategies
Table 5: Adjuvant Systemic Treatment Options for Women With Axillary Node-Negative
Breast Cancer
Table 6: Treatment Options for Women With Axillary Node-Positive Breast Cancer
Table 7: Chemotherapy Drugs and Regimen
Table 8: Summay of Drugs Involved in Breast Cancer Therapy
Table 9: Short Facts Tamoxifen
Table 10: Short Facts Anastrozole
Table 11: Short Facts Letrozole
Table 12: Short Facts Exemestane
Table 13: Short Facts Goserelin
Table 14: Short Facts Fulvestrant.
Table 15: Short Facts Trastuzumab
Table 16 Cancer Immunotherapy Strategies
Table 17: Progress on Ixabepilone
Table 18: Progress on CCI-779.
Table 19: Progress on Fenretinide
Table 20: Progress on Lapatinib
Table 21: Progress on Bevacizumab
Table 22: Progress on Theratope
Table 23: Summary of Mid-Stage to Late stage Investigational Agents Under Development
Table 24: Summary of Breast Cancer Early Stage Pipeline

Some of the companies included in this analysis:
- AstraZeneca
- Baxter International
- Biomira
- Bristol Myers-Squibb
- Eli Lilly
- Genentech
- GlaxoSmithKline
- GTx
- Isis Pharmaceuticals
- Johnson and Johnson
- Lorus Therapeutics
- Merck
- Millennium Pharmaceutical
- NeoRx
- Novartis Pharmaceuticals
- Pfizer
- Roche
- Salmedix
- Schering-Plough
- Wyeth
- YM BioSciences
Some of the drugs included in this analysis:
4HPR
Anastrozole
Arzoxifene
Bevacizumab
Bortezomib
BMS-247550
Erlotinib
Exemestane
Fulvestrant
Gefitinib
Goserelin
Imatinib
KOS-862
Lapatinib
Letrozole
Lonafarnib
NX473
Patupilone
Pemetrexed
Temsirolimus
Theratope
Tipifarnib
Trastuzumab
SDX-105.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Breast Cancer - Therapeutic And Competitive Insights.
    To find out more about Breast Cancer - Therapeutic And Competitive Insights, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Breast Cancer - Therapeutic And Competitive Insights is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Cancer Highlights' category:


Competitive Outlook on Antiangiogenesis and Vascular Targeting in Oncology
Assess opportunities and risks for the continued development of anti-angiogenic and vascular targeting agents in five major cancer indications. Learn More


Lymphoma - A Therapeutic & Competitive Insight
Gain insight into the current challenges and commercial opportunities associated with lymphoma therapy Learn More

Other selected research from the 'R&D' category:


Jak-STAT Signaling Pathway in Oncology Drug Pipeline Update
BioSeeker Group have identified 341 companies plus partners who are today developing 473 Jak-STAT signaling pathway targeting drugs in 1185 developmental projects in cancer across 203 different targets. In addition, there are 8 suspended drugs and another 141 drugs where development has been ceased. Learn More


IL-2 Signaling Pathway in Oncology Drug Pipeline Update
BioSeeker Group have identified 344 companies plus partners who are today developing 449 IL-2 pathway targeting drugs in 1619 developmental projects in cancer across 192 different targets. In addition, there are 6 suspended drugs and another 183 drugs where development has been ceased. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Breast Cancer, Lung Cancer and Antibodies
This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Lung Cancer and by the compound strategy of Antibodies. Learn More


Triple Analysis: Breast Cancer, Leukemia and Lymphoma
This triple analysis focuses on cancer drug development strategies in Breast Cancer, Leukemia and Lymphoma. Learn More